Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
Higher employee pay will be key to running Wake schools smoothly, superintendent says
Recommended
Is pet insurance worth the bark? Survey reveals middling results
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
5.040
-0.230 (-4.36%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,343,310
Open
5.270
Bid (Size)
4.850 (5)
Ask (Size)
5.200 (1)
Prev. Close
5.270
Today's Range
4.980 - 5.345
52wk Range
1.630 - 8.830
Shares Outstanding
98,384,456
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Where Fate Therapeutics Stands With Analysts
April 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
Performance
YTD
+36.59%
+36.59%
1 Month
-28.00%
-28.00%
3 Month
+16.40%
+16.40%
6 Month
+145.85%
+145.85%
1 Year
-20.75%
-20.75%
More News
Read More
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
March 19, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
February 27, 2024
Via
Benzinga
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Recap: Fate Therapeutics Q4 Earnings
February 26, 2024
Via
Benzinga
A Preview Of Fate Therapeutics's Earnings
February 23, 2024
Via
Benzinga
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 27, 2024
Via
Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Fate Therapeutics
November 09, 2023
Via
Benzinga
Recap: Fate Therapeutics Q3 Earnings
November 08, 2023
Via
Benzinga
Earnings Scheduled For February 26, 2024
February 26, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
January 29, 2024
Via
InvestorPlace
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 03, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
November 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.